Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study.
Debdulal ChakrabortyMilan ThakkarRamesh VenkateshSangeeta RoyMaulik BhavsarHelene KarcherPublished in: Clinical ophthalmology (Auckland, N.Z.) (2023)
The study reports on the short-term effectiveness and tolerability of brolucizumab therapy in the management of nAMD in both treatment-naïve and switch eyes. Brolucizumab was observed to have a favourable benefit-risk profile, and study results were within the known safety profile, with no instances of intraocular inflammation.